Pilot study of ribavirin and interferon-beta for chronic hepatitis B. (Q50589743)

16 March 2018

title

Pilot study of ribavirin and interferon-beta for chronic hepatitis B. (English)

1 reference

16 March 2018

1 reference

1 reference

Kakumu S

1

1 reference

16 March 2018

Yoshioka K

2

1 reference

16 March 2018

Wakita T

3

1 reference

16 March 2018

Ishikawa T

4

1 reference

16 March 2018

Takayanagi M

5

1 reference

16 March 2018

Higashi Y

6

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 August 1993

1 reference

16 March 2018

published in

Hepatology

1 reference

16 March 2018

volume

18

1 reference

16 March 2018

issue

2

1 reference

16 March 2018

page(s)

258-263

1 reference

16 March 2018

Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency vir

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

Selective inhibition of functional lymphocyte subpopulations by ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Evaluation of ribavirin in the treatment of acute hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Lassa fever. Effective therapy with ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Inhibition of immune functions by antiviral drugs

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840180206

7 January 2021

Identifiers

DOI

10.1002/HEP.1840180206

1 reference

16 March 2018

1 reference

16 March 2018